Harout Semerjian, President and CEO at Geron Corporation, shared a post on LinkedIn:
“This week, I joined Steve Willey at the 2025 Stifel Healthcare Conference for a fireside chat alongside our CMO, Joseph E. Eid
We highlighted what makes us at Geron motivated every day:
- We have a medicine with the potential to meaningfully impact people living with lower-risk MDS
- We have a team that deeply believes in the science – and understands the urgency of getting it into the hands of clinicians, for the appropriate patients.
- We are aligned on our push to make 2026 our growth year.
We look forward to sharing additional clinical and scientific data at ASH25 next month, reinforcing our conviction in telomerase inhibition and the opportunity ahead.”
More posts featuring Harout Semerjian.